The American Diabetes Association, of Alexandria, Va., appointed Maura Connell chief marketing and communications officer.

Applied Biosystems Group, of Foster City, Calif., appointed William Murray division president of molecular biology.

Aradigm Corp., of Hayward, Calif., appointed Virgil Thompson to its board.

Arena Pharmaceuticals Inc., of San Diego, appointed Louis Lavigne to its board.

ArQule Inc., of Woburn, Mass., appointed William Messenger to its board.

AtheroGenics Inc., of Atlanta, said its president and CEO, Russell Medford, was elected chairman of the Georgia Biomedical Partnership.

AVI BioPharma Inc., of Portland, Ore., appointed Joseph Horn vice president of cardiology.

BioPharma Inc., of Cary, N.C., appointed Larry Tamura director regulatory affairs and quality assurance.

BrainStorm Cell Therapeutics Inc., of Tel Aviv, Israel, appointed Dudy Stolick chief financial officer.

Cardiome Pharma Corp., of Vancouver, British Columbia, appointed Charles Fisher chief medical officer and executive vice president of clinical and regulatory affairs.

CeMines Inc., of Golden, Colo., appointed K.C. Nicolaou co-chairman of its scientific advisory board.

Cyntellect Inc., of San Diego, appointed Tina Nova to its board.

Durect Corp., of Cupertino, Calif., appointed Paula Mendenhall senior vice president of operations.

Dyax Corp., of Cambridge, Mass., appointed Thomas Beck interim manager of medical affairs and clinical operations, and William Schwieterman regulatory adviser.

Ecopia BioSciences Inc., of Montreal, appointed Jacques Jolivet to its scientific advisory board.

Elite Pharmaceuticals Inc., of Northvale, N.J., appointed Edward Neugeboren to its board.

Elusys Therapeutics Inc., of Pine Brook, N.J., appointed Elizabeth Posillico president.

Emergent BioSolutions Inc., of Gaithersburg, Md., appointed Ronald Richard to its board.

EpiCept Corp., of Englewood Cliffs, N.J., appointed Robert Savage and Guy Jackson to its board.

ESBATech AG, of Zurich, Switzerland, appointed Thomas Loeser chief financial officer and Ulrich Feige director of preclinical development.

Evotec OAI AG, of Hamburg, Germany, appointed Mary Tanner to its supervisory board.

Genitope Corp., of Redwood City, Calif., appointed Michael Buckley vice president of manufacturing, and Steven Chamow vice president of process sciences.

Genmab A/S, of Copenhagen, Denmark, said its CEO Lisa Drakeman was appointed to the board and executive committee of the Biotechnology Council of New Jersey.

Illumina Inc., of San Diego, appointed William Rastetter nonexecutive chairman, and promoted John Stuelpnagel to chief operating officer.

Imcor Pharmaceutical Co., of San Diego, appointed Brian Gallagher, Taffy Williams, Robert Ashley, Richard Dean, Darlene Deptula-Hicks, Jonathan Fleming and Alan Watson to its board for 2005.

Neurochem Inc., of Montreal, appointed Shona McDiarmid vice president, intellectual property, and Daniel Delorme vice president, research. It also promoted Philippe Calaise to president of global business, and Denis Garceau to senior vice president of drug development.